Condition: Metastatic Malignant Neoplasm in the Brain · Metastatic Malignant Solid Neoplasm · Sponsor: Mayo Clinic
This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease). Stereotactic radiosurgery (SRS) is a form of radiation therapy that focuses high-power energy on a small area of the body. This trial is being done to determine if single (one) fraction stereotactic radiosurgery is better than fractionated stereotactic radiosurgery or vice versa in controlling tumor and side effects in patients with tumors that have spread to the brain.
This description comes directly from the study's public registry record.
Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Arizona | Scottsdale, Arizona, United States | Recruiting |
| Mayo Clinic in Florida | Jacksonville, Florida, United States | Recruiting |
| Mayo Clinic Health System in Albert Lea | Albert Lea, Minnesota, United States | Not Yet Recruiting |
| Mayo Clinic Health Systems-Mankato | Mankato, Minnesota, United States | Recruiting |
| Mayo Clinic in Rochester | Rochester, Minnesota, United States | Recruiting |
| Mayo Clinic Health System-Eau Claire Clinic | Eau Claire, Wisconsin, United States | Recruiting |
| Mayo Clinic Health System-Franciscan Healthcare | La Crosse, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05222620